StockData
UroGen Pharma Ltd. logo

UroGen Pharma Ltd. (URGN) stock

URGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$29.87+1.77 (+6.30%)

Close on Nov 17, 2026Market cap $1.46BP/E –Yield –

UroGen Pharma enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

UroGen Pharma's enterprise value was $1.36B on Nov 11, 2026, against $1.34B a year earlier. Over the last 5 years it ranged from $54.37M to $2.19B, with a median of $406.06M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$1.36B+24.4%
2025Dec 31, 2025$1.09B+244.1%
2024Dec 31, 2024$316.84M-45.1%
2023Dec 29, 2023$577.62M+220.8%
2022Dec 30, 2022$180.08M+75.2%
2021Dec 31, 2021$102.77M-63.0%
2020Dec 31, 2020$278.10M-48.6%
2019Dec 31, 2019$540.72M-7.4%
2018Dec 31, 2018$583.88M+806.2%
2017Dec 29, 2017$64.43M–

More UroGen Pharma figures

See a number that looks wrong?